{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:32:22Z","timestamp":1759530742080},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T00:00:00Z","timestamp":1422576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologe"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00117-014-2764-x","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T09:04:42Z","timestamp":1422435882000},"page":"136-144","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapienebenwirkungen und Nachsorge bei malignem Melanom"],"prefix":"10.1007","volume":"55","author":[{"given":"T.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,30]]},"reference":[{"key":"2764_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2214\/AJR.12.9049","volume":"200","author":"Abramson","year":"2013","unstructured":"Abramson RG, Abramson VG, Chan E et al (2013) Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol 200(3):475\u2013483","journal-title":"AJR Am J Roentgenol"},{"key":"2764_CR2","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma untergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992\u2013W1000","journal-title":"AJR Am J Roentgenol"},{"key":"2764_CR3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"key":"2764_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.20486","volume":"81","author":"Cross","year":"2006","unstructured":"Cross TJ, Bagot C, Portmann B et al (2006) Imatinib mesylate as a cause of acute liver failure. Am J Hematol 81:189\u2013192","journal-title":"Am J Hematol"},{"key":"2764_CR5","unstructured":"DGHO Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.\u00a0V.: \u201eMelanom Leitlinie, Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen\u201c. https:\/\/dgho-onkopedia.de\/de\/onkopedia\/leitlinien\/melanom\/melanom.pdf"},{"key":"2764_CR6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CMR.0000000000000078","volume":"24","author":"Forschner","year":"2014","unstructured":"Forschner A, Zips D, Schraml C et al (2014) Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 24(5):512\u2013516","journal-title":"Melanoma Res"},{"key":"2764_CR7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ncponc0514","volume":"3","author":"Garni\u00e8re","year":"2006","unstructured":"Garni\u00e8re V, Gr\u00e9goire C, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi\u2019s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339\u2013343","journal-title":"Nat Clin Pract Oncol"},{"key":"2764_CR8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00105-013-2733-8","volume":"65","author":"Gutzmer","year":"2014","unstructured":"Gutzmer R, Hassel JC, K\u00e4hler KC et al (2014) Kutane Nebenwirkungen der medikament\u00f6sen Tumortherapie mit BRAF- und MEK-Inhibitoren. Hautarzt 65:582\u2013589","journal-title":"Hautarzt"},{"key":"2764_CR9","first-page":"212","volume":"9","author":"Hausmann","year":"2011","unstructured":"Hausmann D, Jochum S, Utikal J et al (2011) Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III\/IV malignant melanoma. J Dtsch Dermatol Ges 9:212\u2013222","journal-title":"J Dtsch Dermatol Ges"},{"key":"2764_CR10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1148\/rg.262055097","volume":"26","author":"Hong","year":"2006","unstructured":"Hong X, Choi H, Loyer EM et al (2006) Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 26:481\u2013495","journal-title":"Radiographics"},{"key":"2764_CR11","unstructured":"Information der Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) \u201eTafinlar\u00ae (Dabrafenib)\u201c. http\/\/www.akdae.de\/Arzneimitteltherapie\/NA\/Archiv\/201401-Tafinlar.pdf"},{"key":"2764_CR12","unstructured":"Information der Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) \u201eYervoy\u00ae (Ipilimumab)\u201c. http\/\/www.akdae.de\/Arzneimitteltherapie\/NA\/Archiv\/2011031-Yervoy.pdf"},{"key":"2764_CR13","unstructured":"Information der Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) \u201eZelboraf\u00ae (Vemurafenib)\u201c. http\/\/www.akdae.de\/Arzneimitteltherapie\/NA\/Archiv\/2012042-Zelboraf.pdf"},{"key":"2764_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","volume":"167","author":"Juszczak","year":"2012","unstructured":"Juszczak A, Gupta A, Karavitaki N et al (2012) Ipilimumab: a novel immunmodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1\u20135","journal-title":"Eur J Endocrinol"},{"key":"2764_CR15","first-page":"277","volume":"9","author":"K\u00e4hler","year":"2011","unstructured":"K\u00e4hler KC, Hauschild A (2011) Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 9:277\u2013285","journal-title":"J Dtsch Dermatol Ges"},{"key":"2764_CR16","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2011.38.7886","volume":"30","author":"Maur","year":"2012","unstructured":"Maur M, Tomasello C, Frassoldati A et al (2012) Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 30(6):e76\u2013e78","journal-title":"J Clin Oncol"},{"key":"2764_CR17","unstructured":"Multinational Association of Supportive Care in Cancer: MASCC\/ESMO Antiemetic Guideline 2013. http:\/\/www.mascc.org\/assets\/documents\/mascc_guidelines_english_2013.pdf"},{"key":"2764_CR18","doi-asserted-by":"crossref","first-page":"W241","DOI":"10.2214\/AJR.10.6032","volume":"197","author":"O","year":"2011","unstructured":"O\u2019Regan KN, Jagannathan JP, Ramaiya N, Hodi FS (2011) Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol 197:W241\u2013W246","journal-title":"AJR Am J Roentgenol"},{"key":"2764_CR19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejca.2006.11.014","volume":"43","author":"Pfannenberg","year":"2007","unstructured":"Pfannenberg C, Aschoff P, Schanz S et al (2007) Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43:557\u2013564","journal-title":"Eur J Cancer"},{"key":"2764_CR20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2","volume":"82","author":"Rinne","year":"1998","unstructured":"Rinne D, Baum RP, Hor G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82:1664\u20131671","journal-title":"Cancer"},{"key":"2764_CR21","unstructured":"S3-Leitlinie \u201eMalignes Melanom: Diagnostik, Therapie und Nachsorge\u201c. Version 1.1.- Februar 2013, AWMF Register 023-024OL. http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/032-024l_S3_Melanom_Diagnostik_Therapie_Nachsorge_2013-02.pdf"},{"key":"2764_CR22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","volume":"167","author":"Sinha","year":"2012","unstructured":"Sinha R, Edmonds K, Newton-Bishop JA et al (2012) Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 167:987\u2013994","journal-title":"Br J Dermatol"},{"key":"2764_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OTT.S4833","volume":"3","author":"Tarhini","year":"2010","unstructured":"Tarhini A, Iqbal F (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 3:15\u201325","journal-title":"Onco Targets Ther"},{"key":"2764_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1155\/2013\/857519","volume":"2013","author":"Tarhini","year":"2013","unstructured":"Tarhini A (2013) Immune-mediated adverse events with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013:19","journal-title":"Scientifica"},{"key":"2764_CR25","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C et al (2013) The price of tumor control. An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8(1):e53745. doi:10.j1371\/journal.pone.0053745","journal-title":"PLoS One"},{"key":"2764_CR26","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O et al (2009) A randomized, doubleblind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591\u20135598","journal-title":"Clin Cancer Res"},{"key":"2764_CR27","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691\u20132697","journal-title":"J Clin Oncol"},{"key":"2764_CR28","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamadermatol.2013.5278","volume":"149","author":"Wenk","year":"2013","unstructured":"Wenk KS, Pichard DC, Nasabzadeh T et al (2013) Vemurafenib induced DRESS. JAMA Dermatol 149:1242\u20131242. http\/\/www.akdae.de\/Arzneimitteltherapie\/NA\/Archiv\/201401-Tafinlar.pdf","journal-title":"JAMA Dermatol"},{"key":"2764_CR29","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"2764_CR30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103:129\u2013142","journal-title":"J Natl Cancer Inst"},{"key":"2764_CR31","first-page":"475","volume":"10","author":"Zimmer","year":"2012","unstructured":"Zimmer L, Vaubel J, Livingstone E, Schadendorf D (2012) Nebenwirkungen onkologischer Systemtherapien in der Dermatologie. J Dtsch Dermatol Ges 10:475\u2013487","journal-title":"J Dtsch Dermatol Ges"},{"key":"2764_CR32","unstructured":"Zusammenfassung des EPAR f\u00fcr die \u00d6ffentlichkeit: Glivec\u00ae Imatinib. http:\/\/www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Summary_for_the_public\/human\/000406\/WC500022201.pdf, 2013"}],"container-title":["Der Radiologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-014-2764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00117-014-2764-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-014-2764-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:24:35Z","timestamp":1558589075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00117-014-2764-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,30]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2764"],"URL":"https:\/\/doi.org\/10.1007\/s00117-014-2764-x","relation":{},"ISSN":["0033-832X","1432-2102"],"issn-type":[{"value":"0033-832X","type":"print"},{"value":"1432-2102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,30]]}}}